Deepshekhar Gupta
Education
M.S., health informatics, Weill Cornell Graduate School of Medical Sciences; B.A., economics, Cornell University
Summary of Experience
Mr. Gupta specializes in the application of statistical models and quantitative research methods to evaluate health outcomes, assess the value of cutting-edge therapies in pharmaceutical and medical device markets, and support assessments of complex questions in health care litigation. His experience in health economics and outcomes research (HEOR) includes modeling differences in health care resource utilization and costs between patient cohorts, assessing the patient treatment journey, modeling survival outcomes, as well as analyzing clinical trial data. He also has experience conducting targeted literature reviews and supporting economic modeling and market access strategy cases. In his litigation work, Mr. Gupta has supported experts in assessing economic harm accruing to parties in payer-policyholder and payer-provider disputes. Mr. Gupta has experience analyzing a wide range of datasets, including commercial and public administrative claims, electronic medical records, and clinical trial data.
-
Real-world evidence of Pressure-Enabled Drug Delivery for trans-arterial chemoembolization and radioembolization among patients with hepatocellular carcinoma and liver metastases
Current Medical Research and Opinion, 2024
2024Cook K, Gupta D, Liu Y, Miller-Rosales C, Wei F, Tuttle E, Katz SC, Marshak R, Kim AY
-
Herpes zoster burden in patients with asthma: real-world incidence, healthcare resource utilisation and cost
BMJ Open Respiratory Research, 2024
2024Singer D, Thompson-Leduc P, Ma S, Gupta D, Cheng WY, Muthukumar A, Devine F, Sundar M, Bogart M, Hagopian E, Poston S, Duh MS, Oppenheimer JJ
-
Burden of Herpes Zoster Among Patients with Psoriatic Arthritis in the United States
Psoriasis: Targets and Therapy, 2024
2024Singer D, Thompson-Leduc P, Ma S, Gupta D, Cheng WY, Sendhil SR, Sundar M, Hagopian E, Stempniewicz N, Duh MS, Poston S
-
Real-world evidence of eteplirsen treatment effects in patients with Duchenne muscular dystrophy in the USA
Journal of Comparative Effectiveness Research, 2023
2023 -
Incidence and Risk of Herpes Zoster in Patients with Ulcerative Colitis and Crohn's Disease in the USA
Gastroenterology Report, 2023
2023Singer D, Thompson-Leduc P, Gupta D, Cheng WY, Poston S, Ma S, Pawlowski JE, Duh MS, Morris ED, Devine F, Farraye FA
-
Economic and Clinical Burden of Herpes Zoster Among Patients With Inflammatory Bowel Disease in the United States
Crohn's & Colitis 360, 2023
2023Singer D, Thompson-Leduc P, Gupta D, Poston S, Cheng WY, Ma S, Pawlowski JE, Duh MS, Devine F, Banatwala A, Bernstein E, Farraye FA
-
Incidence of Herpes Zoster in Patients with Rheumatoid Arthritis in the United States: A Retrospective Cohort Study
Journal of Rheumatology, 2023
2023Singer D, Thompson-Leduc P, Poston S, Gupta D, Cheng WY, Ma S, Devine F, Duh MS, Curtis JR
-
Burden of Herpes Zoster Among Patients with Psoriasis in the United States
Dermatology and Therapy, 2023
2023Singer D, Thompson-Leduc P, Ma S, Gupta D, Cheng WY, Sendhil SR, Sundar M, Hagopian E, Stempniewicz N, Duh MS, Poston S
-
Clinical and Economic Burden of Herpes Zoster in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study Using Administrative Claims
Rheumatology and Therapy, 2023
2023Singer D, Thompson-Leduc P, Poston S, Gupta D, Cheng WY, Ma S, Devine F, Enrique A, Duh MS, Curtis JR
-
Disease Progression Stages and Burden in Patients with Duchenne Muscular Dystrophy Using Administrative Claims Supplemented by Electronic Medical Records
Advances in Therapy, 2022
2022Iff J, Zhong Y, Gupta D, Paul X, Tuttle E, Henricson E, Schrader R, CINRG DNHS Investigators
-
National and regional description of healthcare measures among adult Medicaid beneficiaries with schizophrenia within the United States
Journal of Medical Economics, 2022
2022Patel C, Pilon D, Gupta D, Morrison L, Lafeuille MH, Lefebvre P, Benson C
-
A Matching-Adjusted Indirect Comparison of Single-Arm Trials in Patients with Relapsed or Refractory Follicular Lymphoma Who Received at Least Two Prior Systemic Treatments: Tazemetostat was Associated with a Lower Risk for Safety Outcomes Versus the PI3-Kinase Inhibitors Idelalisib, Duvelisib, Copanlisib, and Umbralisib
Advances in Therapy, 2022
2022Proudman D, Nellesen D, Gupta D, Adib D, Yang J, Mamlouk K
-
Effects of metreleptin in patients with lipodystrophy with and without baseline concomitant medication use
Current Medical Research and Opinion, 2021
2021Adamski K, Cook K, Gupta D, Morris E, Tuttle E, Carr E, Cremasco F, Cochran E, Brown RJ
-
Healthcare resource utilization and costs associated with postpartum depression among commercially insured households
Current Medical Research and Opinion, 2020
2020Epperson CN, Huang M, Cook K, Gupta D, Chawla A, Greenberg PE, Eldar-Lissai A
-
Healthcare resource utilization and costs associated with first-line ibrutinib compared to chemoimmunotherapy treatment among Medicare beneficiaries with chronic lymphocytic leukemia
Current Medical Research and Opinion, 2020
2020Huang Q, Emond B, Lafeuille MH, Gupta D, Lefebvre P, Sundaram M, Mato A